Fatty Liver Disease Finding is Monthly Publication Highlight


Feb 10, 2014

Research that shows great promise in the development of a new therapy to treat fatty liver disease is the UK College of Pharmacy Research Publication Highlight for February 2014.

The article was published in Arteriosclerosis, Thrombosis, and Vascular Biology and is entitled, “Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese, db/db mice.”

The research was conducted in the laboratory of Dr. Gregory Graf, Associate Professor in College’s Department of Pharmaceutical Sciences. Collaborators on the project include postdoctoral scholars Drs. Shuang Liang and Kai Su, graduate students Nadezhda S. Sabeva, Yuhuan Wang, Xiaoxi Liu, and Jingjing Liu; and Joshua D. Lester, a graduate student in the UK College of Medicine.

As the publication indicates, cholesterol has long been known to cause cardiovascular disease. However, “an emerging body of literature indicates that cholesterol may also contribute to the development of obesity and the severity of nonalcoholic fatty liver disease.”

This study established proof of principle that accelerating biliary cholesterol secretion would improve dyslipidemia, restore glycemic control and improve measures of fatty liver disease in mice. The findings provide the essential translational data used to garner support for a pilot study to assess Ursodiol/Ezetimibe combination therapy in subjects with fatty liver disease.

“The outstanding research ongoing in Dr. Graf’s laboratory may lead to the development of novel combination therapies for obesity and insulin resistance. Recognition of his work reveals some of the breadth of our faculty’s expertise,” said Linda Dwoskin, Associate Dean for Research.

page last modified: February 19 2014     

© University of Kentucky College of Pharmacy
Official Site of the University of Kentucky College of Pharmacy